Golnaz Ranjbar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Golnaz Ranjbar has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Mohsen Nematy
Department of Nutrition, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran
4 shared publications - Majid Khadem-Rezaiyan
Department of Community Medicine, Medical School, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publications - Reza Rezvani
Department of Nutrition Sciences Mashhad University of Medical Sciences Mashhad Iran
3 shared publications - Andisheh Norouzian Ostad
Department of Nutrition, School of Medicine Mashhad University of Medical Sciences Mashhad Iran
2 shared publications - Hanieh Barghchi
Department of Nutrition Sciences, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 99199-91766, Iran
2 shared publications - Ladan Goshayeshi
Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications
Latest Publications
- Open Access
- 22 May 2023
- Published by Wiley in Food Science & Nutrition
- Vol. 11 (8) , 4398-4408
Animal and plant‐based proteins have different postprandial effects on energy expenditure, glycemia, insulinemia, and lipemia: A review of controlled clinical trials
Dietary proteins have been shown to stimulate thermogenesis, increase satiety, and improve insulin sensitivity in the short and long term. Animal‐based proteins (AP) and plant‐based proteins (PP) have different amino acid profiles, bioavailability, and digestibility, so it seems to have various short‐ and long‐term effects on metabolic responses. This review aimed to compare the findings of controlled clinical trials on postprandial effects of dietary Aps versus PPs on energy expenditure (EE), lipemia, glycemia, and insulinemia. Data are inconclusive regarding the postprandial effects of APs and PPs. However, there is some evidence indicating that APs increase postprandial EE, DIT, and SO more than PPs. With lipemia and glycemia, most studies showed that APs reduce or delay postprandial glycemia and lipemia and increase insulinemia more than PPs. The difference in amino acid composition, digestion and absorption rate, and gastric emptying rate between APs and PPs explains this difference.
- 22 May 2023
- Published by Wiley in Food Science & Nutrition
- Vol. 11 (8) , 4398-4408
Open AccessAnimal and plant‐based proteins have different postprandial effects on energy expenditure, glycemia, insulinemia, and lipemia: A review of controlled clinical trials
Dietary proteins have been shown to stimulate thermogenesis, increase satiety, and improve insulin sensitivity in the short and long term. Animal‐based proteins (AP) and plant‐based proteins (PP) have different amino acid profiles, bioavailability, and digestibility, so it seems to have various short‐ and long‐term effects on metabolic responses. This review aimed to compare the findings of controlled clinical trials on postprandial effects of dietary Aps versus PPs on energy expenditure (EE), lipemia, glycemia, and insulinemia. Data are inconclusive regarding the postprandial effects of APs and PPs. However, there is some evidence indicating that APs increase postprandial EE, DIT, and SO more than PPs. With lipemia and glycemia, most studies showed that APs reduce or delay postprandial glycemia and lipemia and increase insulinemia more than PPs. The difference in amino acid composition, digestion and absorption rate, and gastric emptying rate between APs and PPs explains this difference.
- Open Access
- 1 January 2022
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 25 (1) , 1-12
Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis
Talebi S, et al. Pediatr Gastroenterol Hepatol Nutr. 2022 Jan;25(1):1-12. https://doi.org/10.5223/pghn.2022.25.1.1
- 1 January 2022
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 25 (1) , 1-12
Open AccessFecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis
Talebi S, et al. Pediatr Gastroenterol Hepatol Nutr. 2022 Jan;25(1):1-12. https://doi.org/10.5223/pghn.2022.25.1.1
- 31 August 2021
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 37 (2) , 451-458
Effects of synbiotic supplementation on the serum endotoxin level, inflammatory status, and clinical outcomes of adult patients with critical illness: A randomized controlled trial
Background: Gutmicrobiota dysbiosis, endotoxemia, and systemic inflammation are major factors contributing to disease pathophysiology in patients with critical illness. The present study aimed to assess the effects of synbiotic supplementation on serum endotoxin and inflammationof adult patients with critical illness.Methods: This double‐anonymized, randomized controlled trial was conducted at the intensive care unit (ICU) of Imam Reza Hospital in Mashhad, Iran. In the intervention group, 20 patients received synbiotic capsules (containing a combination of Lactobacillus, Bifidobacterium, Streptococcus, and fructooligosaccharides) twice per day for a maximum of 14 days. In the control group, 18 patients received placebo capsules. The serum levels of endotoxin and C‐reactive protein and the neutrophil to lymphocyte ratio (NLR) were measured before and after the intervention. In addition, clinical outcomes and Acute Physiology and Chronic Health Evaluation and Sequential Organ Failure Assessment scores were recorded.Results: Basic characteristics were similar in the intervention and control groups. The NLR and serum endotoxin levels (median [IQR]) significantly declined in the synbiotic group (7.83 [4.58–12.57] to 6.01 [4.25–9.38]; P = .04; and 11.98 [10.64–12.65] to 10.58 [9.41–12.34]; P = .03, respectively). However, no significant changes were observed in the mentioned parameters in the placebo group. The clinical outcomes were also similar in the study groups, such as the length of hospital/ICU stay and hospital/28‐day mortality rate.Conclusion: Although synbiotic supplementation (500 mg twice daily for 14 days) could reduce serum endotoxin and inflammatory markers, it had no effects on the clinical outcomes of the patients.
- 31 August 2021
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 37 (2) , 451-458
Effects of synbiotic supplementation on the serum endotoxin level, inflammatory status, and clinical outcomes of adult patients with critical illness: A randomized controlled trial
Background: Gutmicrobiota dysbiosis, endotoxemia, and systemic inflammation are major factors contributing to disease pathophysiology in patients with critical illness. The present study aimed to assess the effects of synbiotic supplementation on serum endotoxin and inflammationof adult patients with critical illness.Methods: This double‐anonymized, randomized controlled trial was conducted at the intensive care unit (ICU) of Imam Reza Hospital in Mashhad, Iran. In the intervention group, 20 patients received synbiotic capsules (containing a combination of Lactobacillus, Bifidobacterium, Streptococcus, and fructooligosaccharides) twice per day for a maximum of 14 days. In the control group, 18 patients received placebo capsules. The serum levels of endotoxin and C‐reactive protein and the neutrophil to lymphocyte ratio (NLR) were measured before and after the intervention. In addition, clinical outcomes and Acute Physiology and Chronic Health Evaluation and Sequential Organ Failure Assessment scores were recorded.Results: Basic characteristics were similar in the intervention and control groups. The NLR and serum endotoxin levels (median [IQR]) significantly declined in the synbiotic group (7.83 [4.58–12.57] to 6.01 [4.25–9.38]; P = .04; and 11.98 [10.64–12.65] to 10.58 [9.41–12.34]; P = .03, respectively). However, no significant changes were observed in the mentioned parameters in the placebo group. The clinical outcomes were also similar in the study groups, such as the length of hospital/ICU stay and hospital/28‐day mortality rate.Conclusion: Although synbiotic supplementation (500 mg twice daily for 14 days) could reduce serum endotoxin and inflammatory markers, it had no effects on the clinical outcomes of the patients.
- Open Access
- 1 January 2021
- Published by Korean Society of Clinical Nutrition in Clinical Nutrition Research
- Vol. 10 (4) , 341-352
Macro- and Micro-nutrient Intake Adequacy in Gastric Bypass Patients after 24 Months: a Cross-sectional Study
Ostad AN, et al. Clin Nutr Res. 2021 Oct;10(4):341-352. https://doi.org/10.7762/cnr.2021.10.4.341
- 1 January 2021
- Published by Korean Society of Clinical Nutrition in Clinical Nutrition Research
- Vol. 10 (4) , 341-352
Open AccessMacro- and Micro-nutrient Intake Adequacy in Gastric Bypass Patients after 24 Months: a Cross-sectional Study
Ostad AN, et al. Clin Nutr Res. 2021 Oct;10(4):341-352. https://doi.org/10.7762/cnr.2021.10.4.341
- 9 November 2020
- Published by Wiley in Phytotherapy Research
- Vol. 35 (3) , 1669-1679
Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real‐time two‐dimensional shear wave elastography: A randomized clinical trial
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, while no drugs have been approved for its treatment. The pieces of evidence indicate that propolis as a novel anti‐inflammatory agent might be a promising candidate to treat NAFLD. We aimed to evaluate the efficacy of propolis on hepatic steatosis and fibrosis in patients with NAFLD. This randomized clinical trial was conducted on 54 patients with NAFLD. Patients were randomly assigned to receive propolis tablets at a dose of 250 mg twice daily for 4 months or placebo. The improvement in hepatic steatosis and fibrosis was evaluated using two‐dimensional shear wave elastography. Improvement in the hepatic steatosis was significantly higher in the propolis group than the placebo group, even after adjustment for baseline value and changes in weight, energy intake, and physical activity (odds ratio [OR]: 5.67; 95% confidence intervals [CI]: 1.41–22.8; p = .014). A significant reduction was observed on the liver stiffness in the propolis group (−0.65 ± 0.56 kPa; p = .001), whereas it increased in the placebo group (0.27 ± 0.59 kPa; p = .037). Also, the intake of propolis significantly decreased high‐sensitivity C‐reactive protein (hs‐CRP) levels compared with the placebo group (−0.371; 95%CI: −0.582 to −0.16 mg/L; p = .01). Changes in serum levels of fasting blood sugar, alanine aminotransferase, aspartate aminotransferase, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, cholesterol, and triglyceride did not differ significantly between the two groups (p > .05). There was no significant improvement in insulin resistance in both groups (p > .05). Propolis seems to have protective effects on hepatic steatosis and fibrosis and to reduce the serum levels of hs‐CRP in patients with NAFLD.
- 9 November 2020
- Published by Wiley in Phytotherapy Research
- Vol. 35 (3) , 1669-1679
Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real‐time two‐dimensional shear wave elastography: A randomized clinical trial
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, while no drugs have been approved for its treatment. The pieces of evidence indicate that propolis as a novel anti‐inflammatory agent might be a promising candidate to treat NAFLD. We aimed to evaluate the efficacy of propolis on hepatic steatosis and fibrosis in patients with NAFLD. This randomized clinical trial was conducted on 54 patients with NAFLD. Patients were randomly assigned to receive propolis tablets at a dose of 250 mg twice daily for 4 months or placebo. The improvement in hepatic steatosis and fibrosis was evaluated using two‐dimensional shear wave elastography. Improvement in the hepatic steatosis was significantly higher in the propolis group than the placebo group, even after adjustment for baseline value and changes in weight, energy intake, and physical activity (odds ratio [OR]: 5.67; 95% confidence intervals [CI]: 1.41–22.8; p = .014). A significant reduction was observed on the liver stiffness in the propolis group (−0.65 ± 0.56 kPa; p = .001), whereas it increased in the placebo group (0.27 ± 0.59 kPa; p = .037). Also, the intake of propolis significantly decreased high‐sensitivity C‐reactive protein (hs‐CRP) levels compared with the placebo group (−0.371; 95%CI: −0.582 to −0.16 mg/L; p = .01). Changes in serum levels of fasting blood sugar, alanine aminotransferase, aspartate aminotransferase, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, cholesterol, and triglyceride did not differ significantly between the two groups (p > .05). There was no significant improvement in insulin resistance in both groups (p > .05). Propolis seems to have protective effects on hepatic steatosis and fibrosis and to reduce the serum levels of hs‐CRP in patients with NAFLD.
- Open Access
- 10 June 2020
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 30 (4)
Effects of High-Dose Selenium Supplementation on Oxidative Stress and Inflammatory Markers in Critically Ill Children After Gastrointestinal Surgery: A Randomized Clinical Trial
Background: Pediatric observational studies have indicated that most critically ill children have low serum selenium level, which is associated with the increased incidence of multiple organ failure and deteriorated clinical outcomes. Selenium plays a key role in the endogenous antioxidant defense mechanism and inflammatory pathways. Objectives: The present study aimed to assess the effects of high-dose selenium supplementation on the improvement of inflammatory and oxidative stress indices, as well as clinical outcomes, in pediatric patients with severe oxidative stress and inflammation following major gastrointestinal surgeries. Methods: This prospective, single-blind, randomized, parallel group superiority trial was conducted at the pediatric intensive care unit (PICU) of Akbar Pediatric Hospital in Mashhad, Iran in 2019. Patients were assigned to the supplementation (high-dose selenium: 20 µg/kg/d) and control groups (placebo with the recommended dietary allowance doses of selenium) using stratified blocks. Among 72 eligible critically ill children after gastrointestinal surgery, 66 patients completed the study. Inflammatory markers were measured and compared between the groups, including high-sensitivity C-reactive protein (hsCRP), interleukin 1 beta (IL-1β), prooxidant-antioxidant balance (PAB) assay, and clinical outcomes. Data analysis was performed in SPSS version 20 using the intention-to-treat approach. Results: Only 14 patients had optimal serum selenium concentrations before the surgery and PICU admission. At the end of the study, 90.6% of the patients (n = 29) in the intervention group and 100% (n = 34) of those in the placebo group had suboptimal serum selenium levels (< 50 ng/mL). Although supplementation with high-dose selenium decreased the inflammatory markers in the post-surgical critically ill children (-18 mg/mL and -37.5 pg/mL for hsCRP and IL-1β, respectively), the administered dose could not improve the serum glutathione peroxidase (GPx) concentrations as the selenium functional marker, as well as the PAB assay as the single test to assess the balance/imbalance of the oxidants and antioxidants simultaneously. Additionally, clinical outcomes such as infections, length of ICU stay, and 28-day mortality did not improve after the intervention. Conclusions: According to the results, high-dose selenium supplementation (20 µg/kg/d) in the post-surgical critically ill children could improve the serum inflammatory markers. However, the changes were suboptimal with no significant effects of the serum GPx concentrations, antioxidant defense system, and clinical outcomes.
- 10 June 2020
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 30 (4)
Open AccessEffects of High-Dose Selenium Supplementation on Oxidative Stress and Inflammatory Markers in Critically Ill Children After Gastrointestinal Surgery: A Randomized Clinical Trial
Background: Pediatric observational studies have indicated that most critically ill children have low serum selenium level, which is associated with the increased incidence of multiple organ failure and deteriorated clinical outcomes. Selenium plays a key role in the endogenous antioxidant defense mechanism and inflammatory pathways. Objectives: The present study aimed to assess the effects of high-dose selenium supplementation on the improvement of inflammatory and oxidative stress indices, as well as clinical outcomes, in pediatric patients with severe oxidative stress and inflammation following major gastrointestinal surgeries. Methods: This prospective, single-blind, randomized, parallel group superiority trial was conducted at the pediatric intensive care unit (PICU) of Akbar Pediatric Hospital in Mashhad, Iran in 2019. Patients were assigned to the supplementation (high-dose selenium: 20 µg/kg/d) and control groups (placebo with the recommended dietary allowance doses of selenium) using stratified blocks. Among 72 eligible critically ill children after gastrointestinal surgery, 66 patients completed the study. Inflammatory markers were measured and compared between the groups, including high-sensitivity C-reactive protein (hsCRP), interleukin 1 beta (IL-1β), prooxidant-antioxidant balance (PAB) assay, and clinical outcomes. Data analysis was performed in SPSS version 20 using the intention-to-treat approach. Results: Only 14 patients had optimal serum selenium concentrations before the surgery and PICU admission. At the end of the study, 90.6% of the patients (n = 29) in the intervention group and 100% (n = 34) of those in the placebo group had suboptimal serum selenium levels (< 50 ng/mL). Although supplementation with high-dose selenium decreased the inflammatory markers in the post-surgical critically ill children (-18 mg/mL and -37.5 pg/mL for hsCRP and IL-1β, respectively), the administered dose could not improve the serum glutathione peroxidase (GPx) concentrations as the selenium functional marker, as well as the PAB assay as the single test to assess the balance/imbalance of the oxidants and antioxidants simultaneously. Additionally, clinical outcomes such as infections, length of ICU stay, and 28-day mortality did not improve after the intervention. Conclusions: According to the results, high-dose selenium supplementation (20 µg/kg/d) in the post-surgical critically ill children could improve the serum inflammatory markers. However, the changes were suboptimal with no significant effects of the serum GPx concentrations, antioxidant defense system, and clinical outcomes.
- Open Access
- 1 January 2019
- Published by Korean Society of Clinical Nutrition in Clinical Nutrition Research
- Vol. 8 (2) , 129-137
Pre-pregnancy Body Mass Index and Maternal Nutrition in Relation to Infant Birth Size
Bonakdar SA, et al. Clin Nutr Res. 2019 Apr;8(2):129-137. https://doi.org/10.7762/cnr.2019.8.2.129
- 1 January 2019
- Published by Korean Society of Clinical Nutrition in Clinical Nutrition Research
- Vol. 8 (2) , 129-137
Open AccessPre-pregnancy Body Mass Index and Maternal Nutrition in Relation to Infant Birth Size
Bonakdar SA, et al. Clin Nutr Res. 2019 Apr;8(2):129-137. https://doi.org/10.7762/cnr.2019.8.2.129